Tatva Chintan Pharma Chem Q4 FY26 Results: PAT Rs 10 Cr, Revenue Rs 134 Crore

Tatva Chintan Pharma Chem Q4 FY26 results were declared on May 16, 2026, at the board of directors meeting. Tatva Chintan Pharma Chem reported PAT of Rs 10 crore for the quarter ended March 31, 2026, up 900.0% YoY from Rs 1.00 crore in Q4 FY25, on revenue of Rs 134 crore. Tatva Chintan Pharma Chem is a speciality chemicals company. Investors tracking Tatva Chintan Pharma Chem Q4 FY26 will find complete financial analysis, segment performance, and FY27 outlook in this article.

Click Here – Get Free Investment Predictions

Tatva Chintan Pharma Chem Q4 FY26 Financial Highlights

Metric	Q4 FY26	Comparison
PAT (Net Profit)	Rs 10 crore	up 900.0% YoY from Rs 1.00 crore in Q4 FY25
Revenue from Operations	Rs 134 crore	Quarter ended March 31, 2026
Ticker	TATVA	Sector: Specialty Chemicals

Tatva Chintan Pharma Chem Q4 FY26 Performance Analysis

Tatva Chintan Pharma Chem Q4 FY26 results reflect the company’s operational performance during the January to March 2026 quarter. Tatva Chintan Pharma Chem operates in the specialty chemicals space, a sector benefiting from India’s strong domestic demand growth and structural investment cycle. The Q4 print sets the baseline for FY27 guidance and management commentary on growth strategy.

The profitability trajectory reflects improved operating leverage, better pricing, and strong execution across key business segments. Investors tracking Tatva Chintan Pharma Chem Q4 FY26 will focus on FY27 revenue guidance and margin sustainability. Track Tatva Chintan Pharma Chem on the Univest Screener for live data and analyst ratings.

Check the Univest Screener for live data

Key Factors for Tatva

Revenue Growth and Business Execution

The company’s revenue of Rs 134 crore demonstrates continued momentum in the speciality chemicals business. Q4 is typically the strongest quarter for most Indian companies as year-end government spending, project completions, and seasonal demand peak. The company’s order book, capacity utilisation, and pricing power are key drivers of revenue trajectory.

Margins and Profitability

The firm PAT of Rs 10 crore up 900.0% YoY from Rs 1.00 crore in Q4 FY25 demonstrates the company’s ability to convert revenue growth into bottom-line improvement. EBITDA margin trends will be monitored closely by institutional investors ahead of FY27 guidance.

FY27 Business Outlook

Management commentary from the Q4 FY26 earnings call will cover FY27 revenue guidance, capital expenditure plans, and strategic growth initiatives. India’s macroeconomic environment with 6.5%+ GDP growth, strong infrastructure spending, and rising consumer demand provides a supportive backdrop for FY27 performance across most sectors. Download the Univest iOS App or Univest Android App for live research and alerts.

Frequently Asked Questions on Tatva

What is the company’s PAT?

Ans. Tatva reported PAT of Rs 10 crore up 900.0% YoY from Rs 1.00 crore in Q4 FY25. Results declared May 16, 2026. Full details from NSE/BSE filings. Verify before investing.

What is the company’s revenue?

Ans. The firm’s revenue from operations was Rs 134 crore for the quarter ended March 31, 2026. Track live on the Univest Screener.

When were Tatva results announced?

Ans. The company results were announced on May 16, 2026, at the board meeting approving audited Q4 and FY26 financial statements.

Is Tatva Chintan Pharma Chem a good investment after Q4 FY26?

Ans. Investment decisions require individual assessment of fundamentals, sector outlook, valuation, and risk tolerance. This article is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.